Skip to main content
. 2023 Apr 19;39(9):1439–1453. doi: 10.1007/s12264-023-01060-7

Fig. 3.

Fig. 3

Dual-target anti-stroke drug ZL006-05. ZL006-05 blocks the nNOS-PSD-95 interaction while selectively potentiating ɑ2-containing GABAARs and thereby inhibits NO overproduction and reduces excitability, consequently preventing stroke damage and relieving chronic pain. GABAARs, GABA type A receptors; NMDAR, N-methyl-D-aspartate receptor.